Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 2, Pages 119–127
http://dx.doi.org/10.1155/2013/874212
Research Article

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum

1National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia and Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia
2National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia
3University of Western Australia, School of Medicine and Pharmacology, and Sir Charles Gairdner Hospital, Department of Renal Medicine, Verdun Street, Nedlands, WA 6009, Australia
4School of Population Health, University of Western Australia and Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia
5Biostatistics Center, Massachusetts General Hospital, 50 Staniford Street, Suite 560, Boston, MA 02114-2521, USA
6National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia and Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia

Received 11 June 2013; Accepted 13 July 2013

Academic Editor: Irene Rebelo

Copyright © 2013 Jenette Creaney et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. W. S. Robinson, A. W. Musk, and R. A. Lake, “Malignant mesothelioma,” Lancet, vol. 366, no. 9483, pp. 397–408, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. B. W. S. Robinson and R. A. Lake, “Advances in malignant mesothelioma,” New England Journal of Medicine, vol. 353, no. 15, pp. 1591–1603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Yamaguchi, K. Hattori, M. Oh-Eda, T. Kojima, N. Imai, and N. Ochi, “A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5,” Journal of Biological Chemistry, vol. 269, no. 2, pp. 805–808, 1994. View at Google Scholar · View at Scopus
  4. T. Kojima, M. Oh-Eda, K. Hattori et al., “Molecular cloning and expression of megakaryocyte potentiating factor cDNA,” Journal of Biological Chemistry, vol. 270, no. 37, pp. 21984–21990, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Chang and I. Pastan, “Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 1, pp. 136–140, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. Z. E. Muminova, T. V. Strong, and D. R. Shaw, “Characterization of human mesothelin transcripts in ovarian and pancreatic cancer,” BMC Cancer, vol. 4, article 19, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Scholler, N. Fu, Y. Yang et al., “Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11531–11536, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Hellstrom, J. Raycraft, S. Kanan et al., “Mesothelin variant 1 is released from tumor cells as a diagnostic marker,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 5, pp. 1014–1020, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ho, M. Onda, Q. C. Wang, R. Hassan, I. Pastan, and M. O. Lively, “Mesothelin is shed from tumor cells,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 9, article 1751, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Creaney and B. W. S. Robinson, “Serum and pleural fluid biomarkers for mesothelioma,” Current Opinion in Pulmonary Medicine, vol. 15, no. 4, pp. 366–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Creaney, D. Yeoman, Y. Demelker et al., “Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma,” Journal of Thoracic Oncology, vol. 3, no. 8, pp. 851–857, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Onda, S. Nagata, M. Ho et al., “Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma,” Clinical Cancer Research, vol. 12, no. 14, pp. 4225–4231, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Shiomi, H. Miyamoto, T. Segawa et al., “Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients,” Cancer Science, vol. 97, no. 9, pp. 928–932, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Shiomi, Y. Hagiwara, K. Sonoue et al., “Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma,” Clinical Cancer Research, vol. 14, no. 5, pp. 1431–1437, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Iwahori, T. Osaki, S. Serada et al., “Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin,” Lung Cancer, vol. 62, no. 1, pp. 45–54, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Hollevoet, K. Nackaerts, J. Thimpont et al., “Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 6, pp. 620–625, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Creaney, D. Yeoman, L. K. Naumoff et al., “Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma,” Thorax, vol. 62, no. 7, pp. 569–576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Hollevoet, K. Nackaerts, R. Gosselin et al., “Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma,” Journal of Thoracic Oncology, vol. 6, no. 11, pp. 1930–1937, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Hollevoet, J. Van Cleemput, J. Thimpont et al., “Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study,” Journal of Thoracic Oncology, vol. 6, no. 5, pp. 889–895, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Hollevoet, K. Nackaerts, O. Thas et al., “The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor,” Chest, vol. 141, no. 2, pp. 477–484, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Kagan and A. Brody, “Immunopathology of asbestos-related lung disease,” in Immunopathology of Lung Disease, R. Kradin and B. Robinson, Eds., pp. 421–444, Butterworth-Heinemann, Boston, Mass, USA, 1996. View at Google Scholar
  22. J. Spurzem and S. Rennard, “Immunopathology of idiopathic pulmonary fibrosis,” in Immunopathology of Lung Disease, R. Kradin and B. Robinson, Eds., pp. 119–132, Butterworth-Heinemann, Boston, Mass, USA, 1996. View at Google Scholar
  23. B. Robinson, “Sarcoidosis,” in Immunopathology of Lung Disease, R. Kradin and B. Robinson, Eds., pp. 165–190, Butterworth-Heinemann, Boston, Mass, USA, 1996. View at Google Scholar
  24. R. W. Light, M. I. Macgregor, P. C. Luchsinger, and W. C. Ball Jr., “Pleural effusions: the diagnostic separation of transudates and exudates,” Annals of Internal Medicine, vol. 77, no. 4, pp. 507–513, 1972. View at Google Scholar · View at Scopus
  25. N. Boudville, R. Paul, B. W. S. Robinson, and J. Creaney, “Mesothelin and kidney function-analysis of relationship and implications for mesothelioma screening,” Lung Cancer, vol. 73, no. 3, pp. 320–324, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. A. S. Levey, J. Coresh, E. Balk, A. T. Kausz, A. Levin, and M. W. Steffes, “National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” Annals of Internal Medicine, vol. 139, no. 2, pp. 137–147, 2003. View at Google Scholar
  27. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Google Scholar · View at Scopus
  28. E. R. DeLong, D. M. DeLong, and D. L. Clarke-Pearson, “Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach,” Biometrics, vol. 44, no. 3, pp. 837–845, 1988. View at Google Scholar · View at Scopus
  29. S. D. West and Y. C. G. Lee, “Management of malignant pleural mesothelioma,” Clinics in Chest Medicine, vol. 27, no. 2, pp. 335–354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Segal, G. F. Sterrett, F. A. Frost et al., “A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit,” Pathology, vol. 45, no. 1, pp. 44–48, 2013. View at Publisher · View at Google Scholar
  31. H. E. Davies, R. S. Sadler, S. Bielsa et al., “Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 5, pp. 437–444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Scherpereel, B. Grigoriu, M. Conti et al., “Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 10, pp. 1155–1160, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. O. Topalak, U. Saygili, M. Soyturk et al., “Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study,” Gynecologic Oncology, vol. 85, no. 1, pp. 108–113, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. B. D. Grigoriu, A. Scherpereel, P. Devos et al., “Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment,” Clinical Cancer Research, vol. 13, no. 10, pp. 2928–2935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Hassan, T. Bera, and I. Pastan, “Mesothelin: a new target for immunotherapy,” Clinical Cancer Research, vol. 10, no. 12 I, pp. 3937–3942, 2004. View at Publisher · View at Google Scholar · View at Scopus